CTLA4 and neoplasm: The idea of triple therapy combining anti-PD1/PD-L1 with anti-CTLA4 and an OV has recently become very attractive, with a study in which an Ad in combination with anti-PD-L1 and anti-CTLA4 significantly inhibited tumor growth and prolonged survival in a TNBC orthotopic mouse model.